Epilepsy,one of the most frequent neurological afflictions in men characterized by excessive temporary neuronal discharges resulting in uncontrolled convulsion,inflicts more than 60 million people worldwide [1].Despite the development of several new anticonvulsants,the treatment of epilepsy remains still inadequate.It is roughly estimated that up to 28-30% of patients are poorly treated without the available antiepileptic drugs(AEDs) [2,3].Moreover,many AEDs have serious side effects,and lifelong medication may be required.Therefore,there is a continuing demand for new anticonvulsant agents with more selectivity and lower toxicity.